We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-6.36%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.58B
AUM Growth
-$367M
Cap. Flow
-$23.4M
Cap. Flow %
-1.48%
Top 10 Hldgs %
42.1%
Holding
79
New
5
Increased
1
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$14.7M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$7.59M
3
ASND icon
Ascendis Pharma A/S
ASND
+$6.6M
4
ETNB
89bio
ETNB
+$4.23M
5
COGT icon
Cogent Biosciences
COGT
+$2.9M

Top Sells

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$24.6M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$15M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$14.5M
4
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$5.55M
5
GNCA
Genocea Biosciences, Inc.
GNCA
+$1.42M

Sector Composition

Rank Sector Weight
1 Healthcare 96.9%
2 Financials 0.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRZNW icon
76
Surrozen Inc Warrant
SRZNW
$69.7K
$13K ﹤0.01%
66,666
– –
RARE icon
77
Ultragenyx Pharmaceutical
RARE
$2.45B
– –
-200,000
Closed -$14.5M
ODT
78
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
– –
-4,207,086
Closed -$5.55M
GNCA
79
DELISTED
Genocea Biosciences, Inc.
GNCA
– –
-1,134,453
Closed -$1.42M
1 2 3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Boxer Capital held 79 positions worth $1.58B, down 19% from $1.95B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Boxer Capital's Q2 2022 filing shows 5 new, 1 increased, 2 reduced and 3 closed positions. Its largest new stake was Sarepta Therapeutics: 200,000 shares worth $15M. The largest sale was iTeos Therapeutics, an estimated $24.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q2 2022 buy was Sarepta Therapeutics: 200,000 shares worth $15M.
  • Boxer Capital added most to Turning Point Therapeutics, Inc. Common Stock in Q2 2022, an estimated $7.59M increase.
  • Boxer Capital's biggest Q2 2022 reduction was iTeos Therapeutics, cutting an estimated $24.6M.
  • Boxer Capital fully exited Ultragenyx Pharmaceutical in Q2 2022, selling an estimated $14.5M.
  • Boxer Capital's ten largest holdings make up 42% of its $1.58B portfolio in Q2 2022.
  • Boxer Capital opened 5 new positions and closed 3 in Q2 2022.
  • Boxer Capital's portfolio value fell 19% quarter-over-quarter to $1.58B.

Based on Boxer Capital's 13F filing for Q2 2022, filed 15 Aug 2022.